Vaginitis News and Research

RSS

Vaginitis is described medically as irritation and/or inflammation of the vagina. Vaginitis is a very common disease affecting millions of women each year. The three most common vaginal infections are bacterial vaginosis (BV), candida vaginitis (yeast infection) and trichomonas vaginitis ("trich").

Vaginal infections can produce a variety of symptoms, such as abnormal or increased discharge, itching, fishy odor, irritation, painful urination or vaginal bleeding. When you have vaginitis, you may have some or all of these symptoms.

Understanding the impact of HPV on the vaginal microbiome and its role in cervical cancer

Researchers determine whether cervical cancer risk could be assessed using microflora-derived metabolites in HPV-infected females.

17 Jul 2023

Hydrogel combines nanozymes and probiotics for effective Candida vaginitis treatment

Research introduces FeLab, a responsive hydrogel that combines nanozymes and probiotics for the treatment of Candida vaginitis. FeLab demonstrates effective anti-Candida activity, promotes vaginal mucosa repair, and restores healthy vaginal microbiota, offering a promising therapeutic approach for this condition.

21 May 2023

Vulvovaginitis and the microbiome: a review of the diagnosis and treatment of acute and recurrent infection

Researchers explored the relationship between microbiome and vulvovaginitis.

11 Apr 2023

Does recurrent bacterial vaginosis impact quality of life?

A recent BMC Women's Health study performed a survey to understand how bacterial vaginosis affects women’s quality of life and what treatment they underwent.

22 Mar 2023

Higher incidence of C. glabrata bloodstream infections in patients with diabetes indicates potential fluconazole resistance

In a recent study, researchers analyzed data collected over ten years to understand the clinical characteristics, epidemiology, outcomes, and management of bloodstream Candida infections in diabetes patients.

29 Nov 2022

Psychological and physical impacts of childhood sexual abuse are closely tied, shows study

A new Canadian study reveals that the psychological and physical effects of childhood sexual abuse are closely tied.

22 Sep 2020

SGLT-2 inhibitors do not increase the risk of UTIs in diabetics, concludes study

A new study has shown that SGLT-2 inhibitors used in the treatment of type 2 diabetes do not increase the risk of UTIs over other anti-diabetic medications.

31 Jul 2019

Researcher explores genitourinary health of sexually abused children

For years, scientists and clinicians have been documenting the significant psychological effects on child victims of sexual abuse, but what about the physical impact on their sexual health? Pascale Vézina-Gagnon, a Ph.D. student researcher at the Department of Psychology of Université de Montréal, has examined the issue as part of her doctoral thesis.

19 Dec 2017

Allergan launches first and only oral contraceptive in softgel capsule for prevention of pregnancy

Allergan plc, a leading global pharmaceutical company, today announced the availability of TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1mg/20mcg, the first and only oral contraceptive in a softgel capsule for the prevention of pregnancy

10 Nov 2016

WPI-led study provides clues to new ways to treat difficult-to-cure fungal infections

A study by a multidisciplinary research team, co-directed by Worcester Polytechnic Institute, offers new insights into how virulent fungi adapt through genetic modifications to fight back against the effects of medication designed to block their spread, and how that battle leaves them temporarily weakened. These insights may provide clues to new ways to treat notoriously difficult-to-cure fungal infections like thrush and vaginitis.

7 Jul 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Penn, UGA scientists awarded new contract to develop genome database for microbial pathogens

At the turn of the millennium, the cost to sequence a single human genome exceeded $50 million, and the process took a decade to complete. Microbes have genomes, too, and the first reference genome for a malaria parasite was completed in 2002 at a cost of roughly $15 million. But today researchers can sequence a genome in a single afternoon for just a few thousand dollars. Related technologies make it possible to capture information about all genes in the genome, in all tissues, from multiple individuals.

18 Dec 2014

Chemical compound prevents fungal cells from adhering to surfaces

Targeting serious and sometimes deadly fungal infections, a team of researchers at Worcester Polytechnic Institute (WPI) and the University of Massachusetts Medical School (UMMS) has discovered a chemical compound that prevents fungal cells from adhering to surfaces, which, typically, is the first step of the infection process used by the human pathogen Candida albicans (C. albicans).

14 Aug 2013

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.

25 Sep 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

New diagnostic test for Trichomonas vaginalis

Medical Diagnostic Laboratories, L.L.C. is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

2 Apr 2012

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

Watson Pharmaceuticals, Inc. today announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition often referred to as uterine fibroids (myomas). Leiomyomata are benign solid tumors that often lead to excessive menstrual bleeding, anemia and pain, which ultimately may require surgical intervention.

12 Mar 2012

Merck's NEXPLANON 68 mg now available in the U.S.

Merck today announced that NEXPLANON (etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.

10 Nov 2011

FDA approves two new strengths of Lupron Depot-PED for central precocious puberty

Abbott announced today that the U.S. Food and Drug Administration has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP).

17 Aug 2011

Gen-Probe receives FDA marketing clearance for APTIMA Trichomonas vaginalis assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system.

20 Apr 2011